Value of FGFR alterations on treatment outcomes in bladder cancer: a multicenter collaboration project
Recruiting
- Conditions
- C67C64C56C66C68Malignant neoplasm of bladderMalignant neoplasm of kidney, except renal pelvisMalignant neoplasm of ovaryMalignant neoplasm of ureterMalignant neoplasm of other and unspecified urinary organs
- Registration Number
- DRKS00016925
- Lead Sponsor
- Stratifyer Molecular Pathology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Adult patients =18 years old.
Patients with histologically confirmed advanced bladder cancer.
Patients who have received anti-PD-(L)1 therapy
Exclusion Criteria
< 18 years old.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor recurrance and progression in patients with FGFR-Alterations in advanced urothelial carcinoma after anti-PD-1 or anti-PD-L1 therapies.<br>
- Secondary Outcome Measures
Name Time Method Association of molecular subtype with clinical activity of anti-PD-1 or anti-PD-L1 therapies.